Last edition
News about "Duchenne muscular dystrophy "
Dyne Therapeutics Reports Positive Results from Z-Rostudirsen DMD Study
Dyne Therapeutics reported new 24-month data from the DELIVER trial showing Z-rostudirsen improved cardiopulmonary function in patients with Duchenne Muscular Dystrophy (DMD), building on earlier findings of sustained functional benefits across multiple clinical measures.
Duchenne Muscular Dystrophy | 09/03/2026 | By News Bureau
Chugai Launches Elevidys Gene Therapy for Duchenne Muscular Dystrophy in Japan
Elevidys receives conditional approval and NHI listing for ambulatory DMD patients aged three to under eight years; launch backed by Phase III EMBARK study and strengthened safety measures.
Duchenne Muscular Dystrophy | 23/02/2026 | By News Bureau | 138
Atossa Therapeutics Receives FDA Orphan Drug Designation for Duchenne Therapy
Atossa Therapeutics has received US Food and Drug Administration (FDA) Orphan Drug Designation (ODD) for (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy, further supporting the company’s development programme in rare paediatric neuromuscular diseases.
Duchenne Muscular Dystrophy | 17/01/2026 | By News Bureau
Sarepta Pauses Shipments of Duchenne Gene Therapy Elevidys Amid FDA Safety Review
Sarepta Therapeutics has announced a voluntary and temporary suspension of all US shipments of its Duchenne muscular dystrophy (DMD) gene therapy, ELEVIDYS (delandistrogene moxeparvovec), following the FDA’s distribution suspension request last week.
Duchenne Muscular Dystrophy | 24/07/2025 | By Dineshwori | 428
Somite Therapeutics Receives FDA Orphan Drug and RPDD Designations for SMT-M01
Somite Therapeutics' SMT-M01 program leverages the company's proprietary AlphaStem AI platform to develop a novel cell replacement therapy for DMD.
Duchenne Muscular Dystrophy | 17/09/2024 | By Aishwarya | 720
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy